Article

Case report highlights rationale for neovascular glaucoma treatment

Denver-Intravitreal bevacizumab (Avastin, Genentech) proved to be a successful treatment in a patient with neovascular glaucoma.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
Related Content
J&J gene therapy treatment fails primary endpoints
May 5th 2025

J&J gene therapy treatment fails primary endpoints

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Subrata Batabyal, PhD, receives 2025 Carl Camras Translational Research Award from ARVO Foundation
May 3rd 2025

Subrata Batabyal, PhD, receives 2025 Carl Camras Translational Research Award from ARVO Foundation

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

More companies announce ARVO 2025 presentations
May 2nd 2025

More companies announce ARVO 2025 presentations

Positive interim pilot clinical trial results of PYK-2101
May 2nd 2025

Positive interim pilot clinical trial results of PYK-2101

© 2025 MJH Life Sciences

All rights reserved.